At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 466 enrolled
Drug / intervention
LY2605541 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparison of LY2605541 Versus Insulin Glargine Alone or in Combination With Pre-study Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin: An Open-Label, Randomized Study The IMAGINE 5 Study
In Brief
A Phase 3 clinical trial evaluating LY2605541 and Insulin glargine for Diabetes Mellitus, Type 2. Completed, enrolled 466 participants across 61 sites in 9 countries.
Detailed Summary
The purpose of this study is to compare LY2605541 and insulin glargine using the following measures after participants have been treated for 26 weeks: * Change in participants' overall blood sugar control * The rate of night time low blood sugar episodes * The number of participants that reach blood sugar targets without low blood sugar episodes at night * The rate of low blood sugar episodes reported over a 24-hour period
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesCzechia, Germany, Greece, Israel, Puerto Rico, Romania, Russia, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2012
Enrollment StartMay 2012
Primary CompletionMay 2013
Study CompletionDec 2013
TodayJul 2026
First PostedApr 20, 2012
Enrollment StartMay 1, 2012
Primary CompletionMay 1, 2013
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 14.2 years ago
Interventions
LY2605541drug
Insulin glarginedrug